|
|
Post by Conrad Alvin Lim on May 17, 2006 7:43:34 GMT -4
TD AMERITRADE HOLDING CORP (AMTD)Between 28 April and yesterday, Toronto Dominion Bank dished out more than $378'865'000.00 in open market purchases. The stock has seen very active insider trading in the last two months including a $35M sale from its CEO/Chairman. www.form4oracle.com/company?cik=0001173431&ticker=AMTD Recent Price $ 17.27 52 Week High $ 26.37 52 Week Low $ 13.43 Avg Daily Vol (Mil) 6.486 Mkt. Cap. (Mil) $ 10,530.53 Shares Out (Mil) 609.759 Float (Mil) 513.10
|
|
|
|
Post by Conrad Alvin Lim on May 17, 2006 7:52:08 GMT -4
INTRAWEST CORP (IDR)Pirate Capital LLC 10% Owner - Total Open Market Purchases between 17 Feb and yesterday: $71'332'665.73Hudson Thomas R Jr 10% Owner - Total Open Market Purchases on 2 May: $1'458'368.05 Recent Price $ 35.10 52 Week High $ 37.69 52 Week Low $ 20.26 Avg Daily Vol (Mil) 0.399 Mkt. Cap. (Mil) $ 1,719.694 Shares Out (Mil) 48.994 Float (Mil) 47.00
|
|
|
|
Post by Conrad Alvin Lim on May 17, 2006 8:05:19 GMT -4
SL INDUSTRIES INC (SLI ) STEEL PARTNERS II LP 10% Owner - Total Open Market Purchases between 4 Apr and yesterday $1'268'363.12 Recent Price $ 14.70 52 Week High $ 18.40 52 Week Low $ 13.20 Avg Daily Vol (Mil) 0.005 Mkt. Cap. (Mil) $ 82.536 Shares Out (Mil) 5.615 Float (Mil) 2.40
|
|
|
|
Post by Conrad Alvin Lim on Jun 14, 2006 11:31:57 GMT -4
STRICTLY FOR STOCK INVESTORS. (Not Optionable)Novacea Inc (NOVC) Stock
www.novacea.com Sector: Healthcare Industry: Biotechnology & Drugs   Check out the buying spree on this stock. www.form4oracle.com/company?cik=0001178711&ticker=NOVCConsider this; the last five weeks have tanked most stocks. But this one has not been affected. Financial Report:For the nine months ended 30 September 2005, Novacea, Inc. reported no revenues. Net loss rose 20% to $16.9M. Revenues reflect no grant revenue from US and non US governments. Higher loss reflects increased research & development expenses, higher general & admin. expenses and the presence of stock based employee compensation. Novacea Inc. is an biopharmaceutical Company focused on licensing, developing and commercializing of novel therapies. NewsNovacea Appoints John Walker to Board of Directors 09:00 AM Novacea, Inc. (NASDAQ: NOVC) announced today the appointment of John P. Walker to the company's board of directors. Mr. Walker currently serves as chairman of the boards of directors for Renovis Inc., KAI Pharmaceuticals, Guava Technologies and Saegis Pharmaceuticals. He serves on the boards of directors for Geron Corporation and several privately-held biotechnology companies. Novacea Appoints Paul Laland as Vice President, Corporate... 06/09/06 Novacea, Inc. (NASDAQ: NOVC) announced today that Paul Laland has been appointed Vice President of Corporate Communications. Mr. Laland, with more than 20 years of experience in domestic and international pharmaceutical and biotechnology communications, joins Novacea from VaxGen, Inc., a biopharmaceutical company, where he served as Vice President of Public Affairs. Novacea Announces Exercise of Over-Allotment Option 06/08/06 Novacea, Inc. (NASDAQ: NOVC) announced today that the underwriters of its initial public offering have exercised their over-allotment option to purchase an additional 657,500 shares of common stock. The exercise of the over-allotment option increases the number of shares sold in the initial public offering to 6,907,500 shares, resulting in aggregate gross proceeds to the Company of approximately $44.9 million and, after underwriting discounts, net proceeds of approximately $41.8 million. Market Report -- In Play (NOVC) 06/08/06 Novacea: Study provides support for further development in NSCLC Co announces preliminary results from a Phase 1/2 clinical trial of its investigational product candidate, DN-101 (calcitriol), in... Briefing.com Novacea Announces Preliminary Results of a Phase 1/2 Clinical... 06/08/06 Novacea, Inc. (NASDAQ: NOVC) announced today preliminary results from a Phase 1/2 clinical trial of its investigational product candidate, DN-101 (calcitriol), in second line treatment of non-small cell lung cancer (NSCLC). Novacea to Present at the Pacific Growth Equities 2006 Life... 06/07/06 Novacea, Inc. (NASDAQ: NOVC) announced today that John Curd, MD, the company's president and chief medical officer, will present a corporate overview at the Pacific Growth Equities 2006 Life Sciences Growth Conference in San Francisco. New Data Presented at ASCO Continue to Support Clinical... 06/05/06 Novacea, Inc. (NASDAQ: NOVC) announced today that two of its product candidates, DN-101 and AQ4N, were featured in several oral and poster presentations at the 2006 American Society of Clinical Oncology (ASCO) Annual Meeting held June 2-6 in Atlanta. Penson Worldwide Shares Advance in IPO 05/17/06 NEW YORK (AP) - Penson Worldwide Inc. stock rose 15 percent in its first day of trading Wednesday.
|
|
